MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53
Open Access
- 25 August 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 101 (5), 774-781
- https://doi.org/10.1038/sj.bjc.6605199
Abstract
Interruption of the role of p53s as a tumour suppressor by MDM2 may be one of the mechanisms by which cancer cells evade current therapy. Blocking the inhibition of wild-type p53 by MDM2 in cancer cells should reactivate p53's tumour suppressor functions and enhance current cancer treatments. MI-63 is a novel non-peptide small molecule that has shown strong binding affinity (Ki=3 nM) for MDM2; however, its effects on paediatric cancer cells and the specific mechanism of tumour suppressor reactivation have not been evaluated. Rhabdomyosarcoma (RMS), the most common childhood soft tissue sarcoma, expresses either wild-type or mutant p53 protein. We examined the inhibitory effects of MI-63 in embryonal RMS (ERMS) and alveolar RMS (ARMS) cell lines expressing wild-type or mutated p53. Treatment with MI-63 reduced cell viability by 13.4% and by WAF1, and Bax protein was observed after treatment with MI-63 in RMS cells with wild-type p53, and apoptosis was confirmed by cleaved PARP and caspase-3 expression. However, RD2 and RH30 RMS cells, as well as human normal skeletal muscle cells, showed a minimal increase in p53 signalling and no induction of cleaved PARP and caspase-3. MI-63 was compared with Nutlin-3, a known MDM2 inhibitor, and was found to be more potent in the inhibition of cell proliferation/viability. Further, synergy was observed when MI-63 was used in combination with doxorubicin. These results indicate that MI-63 is a potent therapeutic agent for RMS cells expressing wild-type p53 protein.Keywords
This publication has 24 references indexed in Scilit:
- Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell LymphomaClinical Cancer Research, 2008
- Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar RhabdomyosarcomasCancer Research, 2006
- Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 InteractionJournal of Medicinal Chemistry, 2006
- Mdm2 in growth signaling and cancerGrowth Factors, 2005
- Targeting the p53–MDM2 interaction to treat cancerBritish Journal of Cancer, 2004
- Manipulation of the tumor suppressor p53 for potentiating cancer therapySeminars in Cancer Biology, 2004
- Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcomaLaboratory Investigation, 2004
- Mdm2 association with p53 targets its ubiquitinationOncogene, 1998
- REDUNDANT DOWN-REGULATION PATHWAYS FOR p53Pharmacological Research, 1998
- Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.Genes & Development, 1994